Hunter Syndrome, also known as Mucopolysaccharidosis Type II (MPS II), is being targeted for treatment with RGX-121, a product candidate utilizing the AAV9 vector to deliver the IDS gene encoding the I2S enzyme to the CNS. This innovative approach aims to establish a continuous source of I2S beyond the blood-brain barrier, facilitating long-term correction of […]